Instructions for Authors 2016

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double - spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections:

(a) **First page** including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) **Abstract** not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) **Introduction**; (d) **Materials and Methods/Patients and Methods**; (e) **Results**; (f) **Discussion**; (g) **Acknowledgements**; (h) **References.** All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges.

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org. In case a submission is incomplete, the corresponding Author will be notified accordingly.

Galley Proofs. Galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance by email within two days. For the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific information and additional instructions for Authors

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: http://www.iiar-submissions.com/login.html

In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online annual subscription to Anticancer Research for the current year. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.

2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees. (For further information please click here)

3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.

4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
   • The Instructions to Authors must be followed in every detail.
   • The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
   • The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
   • Figures given in figures should not be repeated in tables.
   • Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
   • Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
   • Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
   • Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
   • Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
   • The References section should provide a complete coverage of the literature as possible including all the relevant works published up to the time of submission.
   • By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.

7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.

8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).

9. Articles submitted to AR may be rejected without review if:
   • they do not fall within the journal's policy.
   • they do not follow the instructions to authors.
   • language is unclear.
   • results are not sufficient to support a final conclusion.
   • results are not objectively based on valid experiments.
   • they repeat results already published by the same or other authors before the submission to AR.
   • plagiarism is detected by plagiarism screening services.
   (Rejection rate (2015): 64%).

10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.

11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org

12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.

13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.

(This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright © 2016 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
General Policy

IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the framework of comparative physiology and pathology. The special focus of the journal is the publication of works on: (a) experimental development and the application of new diagnostic procedures; (b) pharmacological and toxicological evaluation of new drugs and drug combinations; (c) development and characterization of models for biomedical research.

One of the principal aims of IN VIVO is to provide for the prompt publication of accepted articles, generally within 1-2 months from final acceptance.

IN VIVO supports: (a) the aims and the research program of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH (IIAR) (Kapandriti, Attiki, Greece) and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH. The IIAR is a member of UICC.

Editorial Office

International Institute of Anticancer Research, 1st km Kapandriou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

Selection of Recent Articles


Effects of Targeted Proton Radiation on Spinal Cord in a Porcine Model: A Pilot Study. X.W. MAO, M.J. PECAUT, J.D. CAO, D.S. GRIDLEY (Loma Linda, CA, USA)


Radical-scavenging and Anti-inflammatory Activity of Quercetin and Related Compounds and Their Combinations Against RAW264.7 Cells Stimulated with Porphyromonas gingivalis Fimbriae. Relationships between Anti-inflammatory Activity and Quantum Chemical Parameters. Y. MURAKAMI, A. KAWATA, S. ITO, T. KATAYAMA, S. FUJISAWA (Sakado, Saitama; Tokyo, Japan)


Management of Very Early-onset Fetal Growth Restriction: Results from 92 Consecutive Cases. F. HOELLEN, A. BECKMANN, C. BANZ-JANSEN, J. WEICHERT, A. RODY, M.K. BOHLMANN (Lübeck; Mannheim, Germany)

Implementation of a Functional Observation Battery for the Assessment of Postoperative Well being in Rats Subjected to Fimbria-Fornix Transection. L. MARSCHNER, E. WOGENSEN, J. MOGENSEN, K. ABELSON (Copenhagen, Denmark)

Decreased Numbers of CD57+CD3- Cells Identify Potential Innate Immune Differences in Patients with Autism Spectrum Disorder. D. SINISCALCO, T. MIJATOVIC, E. BOSMANS, A. CIRILLO, P. KRUZLIK, V.C. LOMBARDI, K. DE MEIRLEIR, N. ANTONUCCI (Naples; Caserta; Florence; Bari, Italy; Zellik; Brussels, Belgium; Brno, Czech Republic; Reno, NV, USA)


Suppressive Activity of Quercetin on Periostin Functions In Vitro. S. IRIE, M. KASHIWABARA, A. YAMADA, K. ASANO (Yokohama, Japan)

The Prolonged QT Interval: Role of Pro-inflammatory Cytokines, Reactive Oxygen Species and the Ceramide and Sphingosine-1 Phosphate Pathways. P.P. SORDILLO, D.C. SORDILLO, L. HELSON (Quakertown, PA, USA)

Specific Antibodies to Staphylococcus aureus Biofilm Are Present in Serum from Pigs with Osteomyelitis. L.K. JENSEN, H.E. JENSEN, J. KOCH, T. BJARNSHOLT, S. EICKHARDT, M. SHIRTLIFF (Copenhagen, Denmark; Baltimore, MD, USA)
Subscription Order Form 2016

☐ Please enter a Subscription to ANTICANCER RESEARCH Volume 36 (2016).
Annual subscription rates (2016): Institutional, US$ 1898.00 online, US$ 2277.00 online & print; Personal, US$ 897.00 online; US$ 1277.00 online & print; Prices include rapid delivery and insurance.

☐ Please send me the following previous volumes (1-35) at 50% discount on the above rates.
☐ Please invoice.
☐ Please send me information about the International Institute of Anticancer Research (IIAR).

Name and Address: .............................................................................................................. ..................................................
..................................................................................................................................................................................................
Tel: .......................................................................................................................... ...............................................................
Fax: ....................................................................................................................... e-mail: ..............................................
Signature:............................................................................................................... Date:..................................................

Please send this order to ANTICANCER RESEARCH, Subscription Office, IIAR, 1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. Tel & Fax: +30-22950-53389, e-mail: subscriptions@iiar-anticancer.org

Special 2016 Offers to Authors of ANTICANCER RESEARCH

(These offers are open to all authors of articles published in Anticancer Research from 1981-2016 on a basis of priority and availability. Effective from January to December 2016).

● Included in Pubmed, Current Contents and all abstracting and indexing services
● Online with Stanford University HighWire Press
● Open access articles

Please complete and send this order form to:
ANTICANCER RESEARCH, International Institute of Anticancer Research,
1st km Kapandritiou-Kalamou Rd., Kapandriti, P.O. Box 22, Attiki, 19014, Greece. e-mail: subscriptions@iiar-anticancer.org

Special Subscription Order Form 2016

☐ I am one of the authors of the article published in Anticancer Research Vol.…….., pp. ………., year ………..

☐ Please enter my personal subscription to Anticancer Research 2016 (Volume 36) at the special Author’s rate of US$ 465.00 (print or online).

☐ Please send me previous Volume No(s) ……….. at US$ 224.00 (print) per volume.

☐ Please enter my personal combined 2016 subscription to Anticancer Research (Volume 36) and IN VIVO (Volume 30) at US$ 644.00 (print or online).

☐ Please send me an invoice.

Prices include rapid delivery and insurance.

Name and address: .............................................................................................................. ..................................................
..................................................................................................................................................................................................
...........................................................................................................................................................................................
..................................................................................................................................................................................................
Tel-Fax: ....................................................................................................................... e-mail: ..............................................
Date and signature: ..............................................................................................................
Gene Expression in Lipopolysaccharide-treated Human Monocytes Following Interaction with Hepatic Cancer Cells. T. HONDA, H. INAGAWA (Sagamihara-shi; Kita-gun; Niitsu-shi, Japan).................................................. 3699

Global Liver Gene Expression Analysis on a Murine Metabolic Syndrome Model Treated by Low-molecular-weight Lychee Fruit Polyphenol (Oligonol®). H. UCHIYAMA, K. UEHARA, T. NAGASHIMA, A. NAKATA, K. SATO, Y. MIHARA, K.-I. KOMATSU, J. TAKANARI, S. SHIMIZU, K. WAKAME (Tokyo; Atsugi; Sapporo, Japan) ............................................................................................................................................................ 3705


Retrospective Analysis of Growth Speed of 54 Lesions of Colitis-associated Colorectal Neoplasia. K. YAMASAKI, T. MATSUI, T. HISABE, Y. YANO, F. HIRAI, T. MOROKUMA, Y. IWAO, T. MATSUMOTO, H. OHI, A. ANDOH, M. ESAKI, K. AOYAGI, A. SUGITA, H. NAKASE, M. FUJIIYA, D. HIGASHI, K. FUTAMI (Chikushino; Tokyo; Morioka; Kagoshima; Otsu; Fukuoka; Yokohama; Kyoto; Asahikawa, Japan) ................................................. 3731

Adoptive Chemoimmunotherapy Using Activated αβ T Cells for Stage IV Colorectal Cancer. Y. YOSHIDA, M. NAI TO, T. YAMADA, N. AISU, K. DAIBO, T. MERA, T. TANAKA, K. NAITO, K. YASUMOTO, T. KAMIGAKI, S. GOTO, Y. YAMASHITA, S. HASEGAWA (Fukuoka; Tokyo, Japan) ............................................ 3741

Clinical Effects of Orally Administered Lipopolysaccharide Derived from Pantoea agglomerans on Malignant Tumors. A. MORISHIMA, H. INAGAWA (Moriguchi-shi; Miki-cho; Niitsu-shi, Japan) ................................................................................................................................ 3747

Safety of Emulsifying Lipid Formulation Containing Omega-3 Polyunsaturated Fatty Acids for Patients with Crohn’s Disease. A. YASUEDA, S. SHINZAKI, H. IIJIMA, T. MIZUSHIMA, J. NISHIMURA, S. HIYAMA, S. OHNO, T. ITO (Osaka, Japan) ........................................................................................................................................ 3753


Case Report: A Non-small Cell Lung Cancer Patient Treated with GeMAF, Sonodynamic Therapy and Tumor Treating Fields. T. INUI, H. AMITANI, K. KUBO, D. KUCHIIEKE, Y. UTO, T. NISHIKATA, M. METTE (Tokushima; Osaka; Kobe; Tokyo; Kagoshima, Japan).................................................................................................................. 3767

Case Report: GeMAF Treatment in a Patient with Multiple Sclerosis. T. INUI, G. KATSUURA, K. KUBO, D. KUCHIIEKE, L. CHENERY, Y. UTO, T. NISHIKATA, M. METTE (Tokushima; Osaka; Kobe; Kagoshima, Japan)........................................................................................................................................ 3771


Nuclear Y-Box-binding Protein-1 Expression Predicts Poor Clinical Outcome in Stage III Colorectal Cancer. S. SHIRAIWA, T. KINUGASA, A. KAWAHARA, T. MIZOB, O. OHCHI, K. YUGE, S. FUJINO, M. KATAGIRI, S. SHIMOMURA, K. TAJIRI, T. SUDO, M. KAGE, M. KUWANO, Y. AKAGI (Fukuoka, Japan).......................................................................................... 3781
The Organo- and Cytoprotective Effects of Heat-shock Protein in Response to Injury Due to Radiofrequency Ablation in Rat Liver. Y. KAWASHIMA, T. HISAKA, H. HORIUCHI, H. ISHIKAWA, S. UCHIDA, T. KINUGASA, D. ETOU, K. OKUDA, Y. AKAGI (Kurume, Japan) .......................................................... 3591

Dewaxed Brown Rice Contains a Significant Amount of Lipopolysaccharide Pointing to Macrophage Activation via TLRs. H. INAGAWA, T. SAIKA, T. NISIZAWA, C. KOHCHI, M. UENOBE, G.-I. SOMA (Kagawa; Niigata; Wakayama; Aichi, Japan) .......................................................... 3599

5-Aminolevulinic Acid Enhances Ultrasound-mediated Antitumor Activity via Mitochondrial Oxidative Damage in Breast Cancer. Y. SHIMAMURA, D. TAMATANI, S. KUNIYASU, Y. MIZUKI, T. SUZUKI, H. KATSURA, H. YAMADA, Y. ENDO, T. OSAKI, M. ISHIZUKA, T. TANAKA, N. YAMANAKA, T. KURAHASHI, Y. UTO (Tokushima; Kanazawa; Tottori; Tokyo, Japan) .......................................................... 3607

Development of an Evaluation Device for Phagocytic Activity of New Phagocytes Using Simple and pH-sensitive Particles that Do Not Require Pre-treatment. R. ZHANG, Y. KOBAYASHI, K. KAZUMURA, H. TSUCHIYA, N. MORISHITA, H. INAGAWA, G.-I. SOMA (Kagawa; Hamamatsu; Niigata, Japan) .................. 3613

Macrophages Exhibit a Large Repertoire of Activation States via Multiple Mechanisms of Macrophage-activating Factors. Y. SUMIYA, T. INOUE, M. ISHIKAWA, T. INUI, D. KUCHIKE, K. KUBO, Y. UTO, T. NISHIKATA (Kobe; Tokushima; Osaka, Japan) .......................................................... 3619

DBA Lectin Binds to Highly Proliferative Mouse Erythroleukemia Cells. A. SWAIN, K. KULKEAW, Y. TANAKA, Y. NAKANISHI, S. SHIRASAWA, D. SUGIYAMA (Fukuoka, Japan) .......................................................... 3625

Aryl Hydrocarbon Receptor Antagonist StemRegenin 1 Promotes the Expansion of Human Promyelocytic Leukemia Cell Line, NB4. R. KOIDE, K. KULKEAW, Y. TANAKA, A. SWAIN, Y. NAKANISHI, D. SUGIYAMA (Fukuoka, Japan) .......................................................... 3635

An Antitumor 2-Hydroxyarylidene-4-cyclopentene-1,3-Dione as a Protein Tyrosine Kinase Inhibitor: Interaction Between TX-1123 Derivatives and Src Kinase. K. OHKURA, Y. KAWAGUCHI, Y. TATEMATSU, Y. UTO, H. HORI (Suzuka; Choshi; Tokushima, Japan) .......................................................... 3645


Host CD40 Is Essential for DCG Treatment Against Metastatic Lung Cancer. K. YAMASHITA, H. HASEGAWA, M. FUJITA, M. NISHI, T. TANAKA, A. ARIMOTO, S. SUZUKI, T. KAMIGAKI, Y. KAKEJI (Kobe; Osaka; Tokyo, Japan) .......................................................... 3659

Liver Injury After Invariant NKT Cell Activation by Free Alpha-galactosylceramide and Alpha-galactosylceramide-loaded Dendritic Cells. H. HASEGAWA, K. YAMASHITA, D. OTSUBO, Y. KAKEJI (Kobe, Japan) ............... 3667

Screening for Identification of Personalized Food to Promote Adiponecin Secretion in Patients with Cancer. M. SAKAUE, K. MAEDA, S. OHNO, T. ITO (Osaka; Suita, Japan) .......................................................... 3673

Effect of Xenotransplantation Site on MicroRNA Expression of Human Colon Cancer Stem Cells. J. MUKOHYAMA, Y. SHIMO NO, K. YAMASHITA, Y. SUMI, T. MUKOHARA, H. MINAMI, Y. KAKEJI (Kobe, Japan) .......................................................... 3679

Immunopotentiator from Pantoea agglomerans 1 (IP-PA1) Promotes Murine Hair Growth and Human Dermal Papilla Cell Gene Expression. K. WAKAME, H. OKAWA, K.-I. KOMATSU, A. NAKATA, K. SATO, H. INAGAWA, C. KOHCHI, T. NISHIZAWA, G.-I. SOMA (Sapporo; Miki-cho; Takamatsu-shi; Niitsu-shi; Tokyo, Japan) .......... 3687

Effect of Lipopolysaccharide Derived from Pantoea agglomerans on the Phagocytic Activity of Amyloid β by Primary Murine Microglial Cells. Y. KOBAYASHI, H. INAGAWA, C. KOHCHI, K. OKAZAKI, R. ZHANG, G.-I. SOMA (Miki-cho; Kagawa; Niigata, Japan) .......................................................... 3693

Contents continued on the preceding page
Contents continued

Prognostic Factors Including the Expression of Thyroid Transcription Factor 1 (TTF1) in Patients Irradiated for Limited-disease Small Cell Lung Cancer. L. KÄSMANN, S. JANSEN, D. RADES (Lübeck; Hannover, Germany) .................. 3499

Assessment of Outcome After Pancreatoduodenectomy by Junior Surgeons. Y. SHIRAI, H. SHIBA, T. HORIUCHI, N. SAI TO, K. FURUKAWA, T. SAKAMOTO, T. GOCHÔ, Y. ISHIDA, K. YANAGA (Tokyo, Japan) .................. 3505

Second Primary Malignancies in Hepatocellular Cancer – A US Population-based Study. B.K. SHAH, P. KANDEL, A. KHANAL (Sedro-Woolley, WA; Jacksonville, FL; Chicago, IL, USA) .................. 3511

Hepatic Arterial Infusion of Polyethylene Glycol Drug-eluting Beads for Primary and Metastatic Liver Cancer Therapy. C. ALIBERTI, R. CARANDINA, D. SARTI, L. MULAZZANI, V. CATALANO, A. FELICIOLI, P. COSCHIERA, G. FIORENTINI (Padua; Pesaro, Italy) .......................................................................................... 3515


HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. C. CRISCITIELLO, V. BAGNARDI, G. VIALE, D. DISALVATO, N. ROTMENsz, A. ESPOSITO, A. GOLDHIRSCH, G. CURigliano (Milan, Italy) ....................................................................................................... 3537

Prognostic Value of Severe Lymphopenia During Pelvic Concurrent Chemoradiotherapy in Cervical Cancer. O. CHO, M. CHUN, S.-J. CHANG, Y.-T. OH, O.K. NOH (Suwon, Republic of Korea) ............................................. 3541

Nodal Ratio as a Prognostic Factor in Patients with Four or More Positive Axillary Nodes Treated with Breast-conserving Therapy and Regional Nodal Irradiation. G. IATÌ, A. PONTORIERO, S. MONDELLo, A. SANTACATERINA, A. PLATANIA, P. FROSINA, M.M. RASo, D. AIELLO, A. ARCUDI, G. ARENA, G. MARINO, M. MAZZEI, C. RIFATo, E. RISOLETTI, R. RUNCO, G. SANsOTTa, P. DELIA, A. SINdONI, S. PERGOLIZZI (Messina; Taormina, Italy) ........................................................................................................................................................................... 3549

Pilot Study of Intrahepatic Artery Chemotherapy in Combination with Sorafenib in Hepatocellular Carcinoma. V. DINH, S. BHATIA, G. NARAYANAN, J. YRIZARRy, N. SAVARAJ, C. O’BRIEN, P. MARTIN, L. FEUN (Miami, FL, USA) ......................................................................................................................................................................................... 3555

PROCEEDINGS OF THE 19TH ANNUAL MEETING OF THE SOCIETY OF BIOTHERAPEUTIC APPROACHES, 5 December 2015 (Tokyo, Japan) .................................................................................................................................................................................. 3565-3788

Biomimetic Peptides for the Treatment of Cancer (Review). Y. MINE, H. MUNIR, Y. NAKANISHI, D. SUGIYAMA (Fukuoka, Japan) ........................................................................................................................................................................................................................................... 3565

MET Expressed in Glioma Stem Cells Is a Potent Therapeutic Target for Glioblastoma Multiforme. T. TASAKI, M. FUJITA, T. OKUDA, A. YONESHiGE, S. NAKATA, K. YAMASHITA, H. YOSHIOKA, S. IZUMoTO, A. KATO (Osaka; Kyoto; Kobe, Japan) .................................................................................................................................................................................................. 3571

Flow Cytometric Analysis of Ovarian Cancer Ascites: Response of Mesothelial Cells and Macrophages to Cancer. K. HASHIMOTO, K. HONDA, H. MATSUI, Y. NAGASHIMA, H. ODA (Tokyo, Japan) .................................................................................................................................................................................................... 3579

Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells. H. LUO, M. UMEBAYASHI, K. DOI, T. MORISAKI, S. SHIRASAWA, T. TSUNODA (Fukuoka, Japan) .................................................................................................................................................................................................................................................. 3585

Contents continued on the preceding page

Clinical Studies

Early Experience with 70-150 μm Irinotecan Drug-eluting Beads (M1-DEBIRI) for the Treatment of Unresectable Hepatic Colorectal Metastases. O. AKINWANDE, C. SCOOGINS, R.C.G. MARTIN (Baltimore, MD; Louisville, KY, USA) .................................................................................................................................................................................. 3413

Impact of Endoscopic Indocyanine Green Fluorescence Imaging on Superselective Intra-arterial Chemotherapy for Recurrent Cancer of the Skull Base. J. YOKOYAMA, K. ISHIBASHI, H. SHIRAMIZU, S. OHBA (Tokyo; Chiba, Japan) ........................................................................................................ 3419


Male Malignant Phyllodes Breast Tumor After Prophylactic Breast Radiotherapy and Bicalutamide Treatment: A Case Report. P. KARIHTALA, T. RISSANEN, H. TUOMINEN (Oulu, Finland) ........................................................................................................................................................................................................................................ 3433

Bi-weekly Capecitabine–Oxaliplatin (XELOX) plus Bevacizumab as First-line Treatment of Metastatic Colorectal Cancer –The PHOENiX Trial. T. MATSUI, N. NAGATA, K. HIRATA, S. OKAZAKI, S. SATO, M. NAKAMURA, H. KIM, K. OBA, J. SAKAMOTO, H. MISHIMA (Okazaki; Kitakyushu; Fukuoka; Osaka; Yokohama; Matsumoto; Sapporo; Kamigahara; Aichi, Japan) .................................................................................................................. 3437


Impact of Open Laparoscopy in Patients Under Suspicion of Ovarian Cancer. L. SCHRÖDER, C. RUDLOWSKI, P. KUTKUHN, A. ABRAMIAN, C. KAISER, W.C. KUHN, M.-D. KEYVER-PAIK (Bonn, Germany) ........................................................................................................................................... 3459

HIV-related Kaposi’s Sarcoma with Musculoskeletal Involvement in the Modern Antiretroviral Era. P. PAPANASTASOPOULOS, B. ANNAN, A. DALLA PRIA, M. BOWER (London, UK) .................................................................................................................................................................................................................. 3465

Prognostic Factors and Treatment Outcome for Patients with Stage IVB Cervical Cancer. S. OISHI, W. KUDAKA, T. TOITA, T. ARIGA, T. NAKAMOTO, A. WAKAYAMA, Y. NAGAI, I. KANESHIMA, K. NISHIHIRA, Y. OKI (Okinawa, Japan) ........................................................................................................................................................................................................ 3471

Prognosis of Patients with Gestational Trophoblastic Neoplasia and Obstetric Outcomes of Those Conceiving After Chemotherapy. A. GADDUCCI, S. COSIO, A. FANUCCHI, R. TANA, S. MANACORDA, S. PISTOLESI, F.L. STRIGINI (Pisa, Italy) ........................................................................................................................................................................................................... 3477

Outcome of Resection and Chemotherapy versus Chemotherapy Alone for Retroperitoneal Recurrence of Testicular Cancer Involving the Inferior Vena Cava: A Retrospective Cohort Study of 22 Consecutive Patients. G. ILLUMINATI, F.G. CALIO, A.M. ANGELICI, G. PIZZARDI, R. PASQUA, F. MASCI, F. VIETRI (Rome; Catanzaro, Italy) .................................................................................................................................................................................................................. 3483

Laparoscopic Liver Resection Is a Feasible Treatment for Patients with Hepatocellular Carcinoma and Portal Hypertension. N. HARADA, T. MAEDA, T. YOSHIZUMI, T. IKEDA, H. KAYASHIMA, T. IKEGAMI, N. HARIMOTO, S. TAKAKI, Y. MAEHARA (Fukuoka; Hiroshima, Japan) ........................................................................................................................................................................................................... 3489

Contents continued on the preceding page
Inhibitory Effect of Anti-rheumatic Drug Iguratimod for Hepatocellular Carcinogenesis by Inhibition of Serum Interleukin-8 Production. T. SAKAMOTO, Y. ISHII, H. SHIBA, K. FURUKAWA, Y. FUJIWARA, K. HARUKI, R. IWASE, Y. SHIRAI, K. YANAGA (Tokyo, Japan) ................................................................. 3301


The Tumor Suppressor MicroRNA-1 Exhibits Restricted Inhibition of Proliferation of Ovarian Cancer Cells. M.B. STOPE, D. HETTENBACH, A. KAUL, M. PADITZ, K. DIESING, M. BURCHARDT, M. ZYG MUNT, A. MUSTEA, D. KOENSGEN (Greifswald, Germany) ................................................................................................................................. 3329


α-Hexylcinnamaldehyde Synergistically Increases Doxorubicin Cytotoxicity Towards Human Cancer Cell Lines. S. DI GIACOMO, A. DI SOTTO, M.Z. EL-READI, G. MAZZANTI, M. WINK (Rome, Italy; Heidelberg, Germany) ................................................................................................................................. 3347

Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer. B.W. KANG, H.-S. JEON, Y.S. CHAE, S.J. LEE, J.S. PARK, G.S. CHOI, J.G. KIM (Daegu, Republic of Korea) ................................................................................................................................. 3353

Photodynamic Therapy Potentiates the Effects of Curcumin on Pediatric Epithelial Liver Tumor Cells. V. ELLERKAMP, N. BORTEL, E. SCHMID, B. KIRCHNER, S. ARMEANU-EBINGER, J. FUCHS (Tübingen, Germany) ................................................................................................................................. 3363


Enhanced TLR4 Expression on Colon Cancer Cells After Chemotherapy Promotes Cell Survival and Epithelial–Mesenchymal Transition Through Phosphorylation of GSK3β. Y.H. CHUNG, D. KIM (Seoul; Busan, Republic of Korea) ................................................................................................................................. 3383

Clofibrate Demonstrates Efficacy in In Vitro Treatment of Lymphoma and Multiple Myeloma. L.C. SCHMEEL, F.C. SCHMEEL, I.G.H. SCHMIDT-WOLF (Bonn, Germany) ................................................................................................................................. 3395